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Abstract
Survival analysis methods such as Cox regression can be used in infectious disease research
to compare the timing of clinical events between treatment or exposure groups.
Randomized clinical trials are the gold standard for estimating the effect of a treatment or
exposure on a survival time endpoint. However, clinical trials are not always ethical or
feasible. In that case, inference about the effect of interest might be attempted using data
from observational studies. Unfortunately, observational studies may be riddled with
confounding which can cast doubt on the validity of the results. In this tutorial, we
demonstrate how inverse probability weighted Cox models can be used to account for
multiple measured confounders, while concentrating inferences on the treatment or
exposure effects of central interest and providing graphical summaries of these effects.
This approach is illustrated using an example that estimates the effect of injection drug use
on AIDS-free survival among HIV-infected women.

Key Words: Bias; Censoring; Cohort studies; Confounding; Cox proportional hazards
model; Inverse probability weights; Standardization; Survival analysis; Time-to-event

Objective: The primary objective of this paper is to familiarize the reader with inverse
probability weighted Cox models.
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Survival analysis can be used in infectious disease research to compare the time to
occurrence of clinical events between treatment or exposure groups (1). Randomized trials
are the gold standard to estimate exposure effects on survival time, but are not always
ethical or feasible. Although observational studies may provide estimates of effects when
trial data are unavailable, the estimates they yield are often riddled with confounding (2).
Informally, confounding occurs when the exposure and outcome share a common cause.
The Cox proportional hazards regression model (3), the standard approach in survival
analysis, can account for multiple measured confounders. Unfortunately, the Cox model
provides only a single summary measure (i.e., hazard ratio), which can be difficult to
interpret (4).
As an alternative to the standard Cox model, we present a method in this paper that
uses inverse probability (IP) weights to estimate the effect of an exposure that is fixed at
study entry. Under certain assumptions, this method can be used to mimic a randomized
trial when only observational data is available. In particular, unlike the standard Cox
model, this approach allows for estimation of marginal effects which compare the
distribution of outcomes when the entire population is exposed versus when the entire
population is unexposed (5). This IP-weighted approach naturally leads to Kaplan-Meier
(6) type survival curve estimates that account for confounding by multiple covariates (7,
8). Herein, we refer to IP weighting as standardization, where the standardization is to the
entire population under two different exposures (7, 9). We illustrate this standardization
method through an example that estimates the effect of injection drug use (IDU) on AIDSfree survival among HIV-infected women.
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Motivating Example: AIDS-Free Survival Among Injection Drug Users
The Women’s Interagency HIV Study (WIHS) is a prospective, observational,
multicenter study of women living with HIV and women at-risk of HIV infection in the US
(10). A total of 4,129 women (1,065 HIV-uninfected) were enrolled between October 1994
and December 2012 at six US sites. An institutional review board at each site approved
study procedures and all study participants provided written informed consent. We were
interested in determining if AIDS-free survival among HIV-infected women differed by IDU,
accounting for possible confounding by factors measured at baseline and during study
follow-up. We estimated the hazard ratio and the absolute risk difference at ten years to
quantify this effect.
The study sample consisted of 1,164 women enrolled in WIHS who were alive, HIVinfected, and free of AIDS on 6 December 1995 (11). The endpoint was either death or a
diagnosis of AIDS. Women who did not reach this endpoint by 6 December 2005 were
censored at that time or at their last visit where they were known to be alive and AIDS-free,
whichever came first. A history of IDU at WIHS enrollment is denoted as 𝑋 = 1 (𝑋 = 0
otherwise). Denoted as the list (or vector) 𝒁, the baseline covariates are: African American
race, age, and nadir CD4 count (in cells/uL) measured from WIHS enrollment to baseline
(i.e., 6 December 1995). Also, let 𝑍(𝑡) denote the time-varying covariate antiretroviral
(ART) initiation during study follow-up, where 𝑍(𝑡) = 1 if an individual starts ART by time
t since baseline and 𝑍(𝑡) = 0 otherwise.

Inverse Probability Weighted Cox Models
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Researchers are often interested in estimating effects of an exposure fixed at study
entry. IP-weighted Cox models are a method to compare the timing of clinical events under
two different exposures, mimicking results in randomized trials. An IP-weighted Cox model
is fit by maximizing a weighted partial likelihood, where participant i who died or was
diagnosed with AIDS at time t from baseline contributes the term {exp(𝛽𝑋𝑖 ) /
∑𝑗∈𝑅(𝑡) 𝑤
̂𝑗 (𝑡) exp(𝛽𝑋𝑗 )}

̂ 𝑖 (𝑡)
𝑤

, where 𝑅(𝑡) is the risk set at time t and exp(𝛽) is the hazard

ratio for a unit difference in exposure X accounting for confounding measured by covariates
through the estimated IP weight 𝑤
̂𝑖 (𝑡) (discussed below) (12). Slight modification of the
likelihood is needed in the presence of tied survival times. The robust variance estimator
(13) can be employed to account for the fact that the IP weights are estimated (14). See the
Appendix A for a review of inference for the standard (i.e., unweighted) Cox proportional
hazards model.
The estimated IP weight 𝑤
̂𝑖 (𝑡) is the product of an estimated time-fixed IP exposure
weight 𝑤
̂1𝑖 and an estimated time-varying IP drop out weight 𝑤
̂2𝑖 (𝑡) for each participant 𝑖
at each survival time t. The time-fixed IP exposure weights are constructed to account for
confounding by covariates measured at baseline. Different versions of these weights have
been proposed. We recommend the stabilized IP exposure weight 𝑤1𝑖 defined as the ratio
of the marginal probability of having the exposure that participant i had, formally
𝑃(𝑋𝑖 = 𝑥𝑖 ), to the covariate-conditional probability of having the exposure that participant
i had, formally 𝑃(𝑋𝑖 = 𝑥𝑖 |𝒁𝑖 ), where 𝒁𝑖 are the measured covariates for participant i
assumed sufficient to adjust for confounding. If we do not appropriately adjust for
confounding, the estimated association between the exposure and study outcome may be
far from the truth (i.e., biased). Because these IP weights are unknown, the probabilities of
IP-weighted Cox models
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exposure are estimated using the observed data. Estimation details are provided in the
following section tailored to the example.
The time-varying IP drop out weights are constructed to account for possible
selection bias due to drop out (12). Participants last observed alive and AIDS-free more
than one year prior to 6 December 2005 were considered drop outs (i.e., loss to follow-up).
Participants receive a time-varying weight that corresponds to their probability of
remaining free from drop out. This stabilized IP weight 𝑤2𝑖 (𝑡) is defined as the ratio of the
marginal probability of remaining free of drop out, formally 𝑃(𝐷𝑖 > 𝑡|𝑋𝑖 ), where 𝐷𝑖 is the
time from baseline to drop out for participant i, to the covariate-conditional probability of
remaining free of drop out, formally 𝑃(𝐷𝑖 > 𝑡|𝒁𝑖 , 𝑍𝑖 (𝑡), 𝑋𝑖 ), where 𝒁𝑖 and 𝑍𝑖 (𝑡) are the
measured common causes of drop out and the study outcome for participant i up to time t.
(Note the covariates in the drop out model can be different than the covariates in the
exposure weight model). If we do not appropriately adjust for the common (time-varying)
causes of drop out and study outcome, the estimated association between the exposure and
outcome may be biased due to drop out. Again, because these IP drop out weights are
unknown, the probabilities of remaining free of drop out are estimated using the observed
data. Estimation details are provided in the following section tailored to the example.
Standardized survival curve estimates can be obtained by fitting an IP-weighted Cox
model stratified by exposure with no covariates and then nonparametrically estimating the
baseline survival functions for the two strata (7). In the absence of weighting, these
survival curve estimates will be (asymptotically) equivalent to Kaplan-Meier estimates
obtained separately for each of the exposure strata (15).
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For all Cox models presented below, we employed Efron’s method to account for
events that occurred on the same date(16). We obtained confidence intervals for the risk
difference at 10 years using a nonparametric bootstrap using 200 random samples with
replacement (17). The data analysis for this paper was conducted using SAS software
version 9.3 (SAS Institute Inc., Cary, NC). SAS code for analyses in the present paper is
provided in the Electronic Supplement.

Illustrative Example
The 1,164 women were 58% African American, median age was 36 years, and
median nadir CD4 count was 349 cells/uL at baseline (Table 1). At enrollment, 38% of
women reported a history of IDU. During follow-up, 667 (57%) of women initiated ARTs.
Women were followed for up to 10 years with a total of 7,090 person-years during which
579 (50%) developed AIDS or died, and 117 (10%) dropped out of the study.
In analyses that did not account for covariates, women with a history of IDU had
notably worse AIDS-free survival than women without a history of IDU (Figure 1). The
estimated hazard ratio from the unadjusted Cox model was 1.72 (95% confidence interval
(CI): 1.46, 2.03; Wald P value < 0.001), suggesting that the hazard of AIDS or death for
those with a history of IDU was almost twice the hazard of those without a history of IDU
(Table 2). We assessed the proportional hazards assumption graphically by examining
whether the log cumulative hazard function estimates (Supplemental Figure 1) were
approximately parallel. We also assessed this assumption statistically by inclusion of a
product term between history of IDU and time in the Cox model, for which the Wald P value
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was 0.40. Neither graphical nor statistical assessment suggested a meaningful departure
from proportional hazards.
We then obtained a standardized hazard ratio estimate from the IP-weighted Cox
model, which involved two steps. In the first step, using separate logistic regression
models, weights were estimated for the probability of exposure (i.e., history of IDU) and for
the probability of not dropping out. For the exposure weights, we fit logistic regression
models for both the numerator and denominator. The exposure model for the numerator
had no covariates, while the exposure model for the denominator included age, race, and
nadir CD4 count, as well as all pairwise interactions. Age and nadir CD4 were included as
continuous variables using restricted quadratic splines with four knots placed at 5 th, 35th,
65th, and 95th percentiles (18). For the drop out weights, time was coarsened into months
since baseline (19). Then, using pooled logistic regression(20), the drop out model for the
numerator included only exposure (i.e., history of IDU) and time (using restricted quadratic
splines), while the drop out model for the denominator included exposure, time (spline),
age (spline), race, nadir CD4 count (spline), and ART initiation (time-varying), as well as all
pairwise interactions. In the pooled logistic regression model, each person contributed up
to 120 records and the weights were cumulatively multiplied for each person. The
estimated weights 𝑤
̂𝑖 (𝑡) had a mean of 1.00 (with a standard deviation of 0.70), and ranged
from 0.46 to 10.85 (Supplemental Table 1). In the second step, the IP-weighted Cox model
was fit by weighting participants by their estimated weights, with outcome time to AIDS or
death, and history of IDU as the sole covariate.
We obtained the estimated survival functions from an IP-weighted Cox model with
no covariates stratified by history of IDU. After standardization for confounding and drop
IP-weighted Cox models
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out by IP weighting, survival curves (Figure 2) showed an attenuated difference in AIDSfree survival compared to the survival curves without accounting for any covariates (Figure
1). Under certain assumptions discussed below, the dashed curve can be interpreted as an
estimate of the AIDS-free survival if (contrary to fact) everyone had a history of IDU at
enrollment, while the solid curve can be interpreted as an estimate of the AIDS-free
survival if (contrary to fact) no one had a history of IDU at enrollment (7, 8). The
standardized hazard ratio from the IP-weighted Cox model was 1.53 (95% CI: 1.27, 1.85;
Wald P value < 0.001) (Table 2). We again assessed the proportional hazards assumption
graphically by examining whether the IP-weighted log cumulative hazard function
estimates (Supplemental Figure 2) were approximately parallel. We also assessed this
assumption statistically by inclusion of a product term between history of IDU and time, for
which the Wald P value was 0.11. Neither graphical nor statistical assessment suggested a
meaningful departure from proportional hazards. From the standardized survival curves,
the ten-year risk of AIDS or death was 0.60 if (contrary to fact) everyone had a history of
IDU at enrollment and 0.46 if (contrary to fact) no one had a history of IDU at enrollment.
The 10-year risk difference was 0.14 (bootstrap 95% CI: 0.06, 0.22). For comparison, we
also estimated a covariate-adjusted hazard ratio by including history of IDU, age (spline),
race, and nadir CD4 count (spline) directly in an unweighted Cox model. The covariateadjusted hazard ratio estimate was 1.62 (95% CI: 1.35, 1.95; Wald P value < 0.001).

Discussion
IP-weighted Cox models and standardized survival curves were presented as a
method to compare the timing of clinical events for two different exposure conditions,
IP-weighted Cox models
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mimicking results in randomized trials under certain assumptions. We compare this
method to the traditional covariate-adjusted Cox model and discuss assumptions and
caveats below.
Although hazard ratio estimates from the two approaches were comparable in the
WIHS example above, the standardized (i.e., IP-weighted) method provides several
potential benefits over the covariate-adjusted method. First, the standardized approach can
be used to mimic a randomized trial when only observational data is available (under
certain assumptions discussed below). In particular, the estimated hazard ratio using the
standardized approach can be interpreted the same as the (marginal) hazard ratio one
would obtain in a randomized experiment such as a clinical trial where there is no
confounding. In contrast, a covariate-adjusted Cox model hazard ratio does not necessarily
equal the marginal hazard ratio, even in the absence of confounding, because the Cox model
is not collapsible for the hazard ratio parameter(21). A regression model is said to be
collapsible for a parameter (in this case, the hazard ratio) if the covariate-adjusted
parameter is the same as the unadjusted parameter (22).
Second, the IP weighting approach yields standardized survival curve estimates.
Although the hazard ratio is a common summary parameter to compare survival
distributions between exposure groups, there are drawbacks to focusing inference on
hazard ratios. For instance, the hazard ratio can be difficult to interpret, especially when
trying to summarize the effect of a treatment or exposure (4). Presenting estimated
survival curves is an alternative to reporting hazard ratios that may be more interpretable
because survival curves summarize all information from baseline up to any time t. The IPweighted approach leads to Kaplan-Meier type survival curve estimates that are
IP-weighted Cox models
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standardized to the entire population under two different exposures at baseline while
accounting for confounding by multiple covariates. A covariate-adjusted Cox model does
not afford such survival curve estimates (5, 8).
Third, the IP-weighted approach with drop out weights requires a weaker
assumption about censoring than the Cox model. Specifically, if there are measured timevarying covariates predictive of censoring and survival time, the IP-weighted approach will
yield consistent estimates of the hazard ratio, while the covariate-adjusted approach will
not (15, 23). The use of IP drop out weights also yields estimators that are more efficient
(i.e., less variable) than those from the covariate-adjusted Cox model, even when there is no
selection bias (23).
Estimation of the hazard ratio and survival curves using standardization by IP
weights requires certain assumptions to yield valid inference about the exposure effect. In
particular, this approach assumes positivity, well-defined exposures, correctly specified
models, and no unmeasured confounding or selection bias. For each level defined by the
covariates, positivity means that there is a positive probability of each level of exposure
(14). Well-defined exposures imply that there are not multiple versions of exposure, or if
there are, that they are unimportant (14). The standardized hazard ratio estimator and
survival curves require correctly specified IP weights (i.e., correct covariate functional
forms). It is also assumed that sufficient sets of covariates have been measured to
effectively address confounding (i.e., no unmeasured confounding) (7, 12) and selection
bias due to drop out (23).
Drop out weights can be included in the IP-weighted Cox model to adjust for
baseline and time-dependent covariates predictive of both censoring and survival time (24IP-weighted Cox models
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26). In the example, the time-varying covariate ART initiation was not included in the
covariate-adjusted Cox model. Typically, when assessing the effect of a baseline exposure,
one would not adjust for post-baseline covariates because such covariates may be on the
causal pathway from the exposure to the outcome. Thus, adjusting for post-baseline
covariates may lead to attenuated estimates of the total effect of the exposure (26-28). On
the other hand, time-varying ART initiation may be predictive of both drop out and the
survival time, so excluding that variable from the Cox model has the potential to introduce
selection bias. In contrast, the use of IP drop out weights provides a valid approach to
adjusting for a time-varying covariate associated with drop out and survival (19).
We only discussed exposure groups defined at baseline. When interest focuses on
exposures that change over time, methods must be adapted accordingly. When a timevarying confounder is a risk factor for the outcome, predicts later exposure, and is affected
by prior exposure, standard statistical methods (e.g., Cox models with time-varying
covariates) are biased and fail to provide consistent estimators of effects (29-32). IP
weighting can be generalized to account for time-varying confounders (12). For example, in
HIV-infected individuals, CD4 count is a risk factor for death, predicts subsequent
treatment with antiretroviral therapy, and is affected by prior treatment; thus, the IPweighted Cox model is appropriate for studying the effect of time-varying antiretroviral
therapy on overall survival while adjusting for time-varying CD4 count.
We suggest using expert knowledge to determine which covariates to adjust for
prior to model fitting. Many epidemiologists would retain a possible confounder if its
inclusion changes the estimate of association by more than 10% or 20% and a great deal of
precision is not sacrificed (33). More principled approaches for determining which
IP-weighted Cox models
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covariates to adjust for in a model include conditioning on all causes of the exposure or
outcome (34) and constructing causal directed acyclic graphs (based on a priori beliefs or
knowledge) to posit a sufficient set of covariates to block all back door paths (35). For the
weight models, covariates that are unrelated to the exposure but related to the outcome
yield effect estimates with smaller variance and no increase in bias, so they should be
included in the model; however, covariates that are related to the exposure but not to the
outcome lead to effect estimates with larger variance and no reduction in bias, so they
should be excluded from the model (36). Machine learning techniques (37, 38) can be used
as an alternative approach to logistic regression for estimating weights.
Although the IP-weighted method used to analyze the WIHS data attempts to adjust
for confounding and selection bias, the conclusions from the analysis are still subject to the
following considerations. Comparisons of groups from observational studies may be
subject to unmeasured confounding bias, as the assumption of no unmeasured confounding
is untestable. Similarly, the IP-weighted method assumes drop out is independent of the
survival time conditional on observed baseline and time-varying covariates. The absence of
unmeasured covariates predictive of both the censoring mechanism and survival time is
also an untestable assumption. Finally, as with all methods, error in the measurement of
exposure, covariates, or the event status or times could bias the results(39).
In conclusion, we have presented an example of survival data pertinent to infectious
disease research and illustrated how to compare groups of study participants using the IPweighted Cox proportional hazards model. The methods presented here, and in the prior
companion review paper (1), have broad applicability in infectious disease research.
Careful use of this and other methods for survival analysis will continue to enrich the
IP-weighted Cox models
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evidence base in the field of infectious diseases by providing answers to questions that are
difficult or impossible to answer well without explicitly accounting for time. Inverse
probability weighted Cox models provide a method to estimate covariate-standardized
hazard ratios and survival curves in observational studies, and obtain information about
effects of treatments or exposures to prevent infectious diseases or their sequela.

IP-weighted Cox models
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Appendix: Review of the Standard (Unweighted) Cox Proportional Hazards Model
Let uppercase letters denote random variables and lowercase letters possible
realizations of random variables or constants. Let 𝑖 = 1, … , 𝑛 index the study participants.
Let 𝑇𝑖 be the time from baseline to AIDS diagnosis or death, 𝐷𝑖 be the time from baseline to
study drop out, and 𝐶𝑖 be the time from baseline to administrative censoring. In practice,
only the minimum of 𝑇𝑖 , 𝐷𝑖 , and 𝐶𝑖 is observed, denoted by 𝑇𝑖∗ = min(𝑇𝑖 , 𝐷𝑖 , 𝐶𝑖 ). See the first
paper in this tutorial series for a review of survival, hazard, and log cumulative hazard
functions (1).
The Cox proportional hazards regression model (3) is one of the most widely used
statistical methods in biomedical research. The univariate Cox model is defined as ℎ𝑖 (𝑡) =
ℎ0 (𝑡)exp(𝛽𝑋𝑖 ), where ℎ𝑖 (𝑡) is the hazard function for individuals with covariate 𝑋𝑖 , ℎ0 (𝑡) is
the reference hazard at time t for those with 𝑋𝑖 = 0, and 𝛽 is the log hazard ratio for a one
unit change in 𝑋𝑖 .
Heuristically, Cox regression may be understood as a series of logistic regression
models, where at each ordered survival time, the log odds of the event are regressed on the
exposure groups and any covariates (16). The Cox model is a semiparametric model
because no assumption is placed on the probability distribution for the reference survival
time distribution. Equivalently, the function ℎ0 (𝑡) is left arbitrary. The parameters of a Cox
model are estimated using maximum partial likelihood (40). Assuming no tied survival
times, participant i who had the event at time t contributes the term exp(𝛽𝑋𝑖 ) /
∑𝑗∈𝑅(𝑡) exp(𝛽𝑋𝑗 ) to the partial likelihood function, where 𝑅(𝑡) is the set of participants at
risk at time t. For the case of a single covariate 𝑋𝑖 , the partial likelihood is defined as simply
a product of these individual contributions for events, or
IP-weighted Cox models
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𝐿(𝛽) =

∏𝑛𝑖=1 [
∑

exp(𝛽𝑋𝑖 )

𝑗∈𝑅(𝑇𝑖 ) exp(𝛽𝑋𝑗 )

𝑌𝑖

] , where 𝑌𝑖 is an event indicator (i.e., 𝑇𝑖∗ = 𝑇𝑖 ). Only events

contribute to the numerator of the likelihood due to the exponent 𝑌𝑖 . There are several
ways to handle tied survival times, including methods ascribed to Peto and Breslow (41,
42), Efron (16) and an exact approach (26), which all return the same results if there are no
ties. In the presence of moderate ties and if time is truly continuous, Efron’s approximation
performs well compared to the other approaches (43).
One of the central assumptions of the Cox model is that the ratios of the hazards
defined by levels of the covariates are constant over time. This is the proportional hazards
assumption. The proportional hazards assumption can be assessed by fitting the model
ℎ(𝑡) = ℎ0 (𝑡)exp(𝛽1 𝑋𝑖 + 𝛽2 𝑋𝑖 𝑡) and testing the null hypothesis that 𝛽2 = 0, where 𝑋𝑖 𝑡 is a
product of the covariate and time t, or some monotonic function of time, such as log(t).
In general, a 1 − 𝛼 Wald confidence interval (CI) for the hazard ratio is defined as
exp (𝛽̂ ± 𝑧1−𝛼/2 √𝑉̂ (𝛽̂)), where 𝑧1−𝛼/2 is the 1 − 𝛼/2 percentile of a standard normal
distribution and 𝑉̂ (𝛽̂) is the estimated variance of 𝛽̂ . A Wald test statistic is defined as
2

(

̂
𝛽

) and is chi-squared distributed with 1 degree of freedom under the null

̂)
̂ (𝛽
√𝑉

hypothesis 𝛽 = 0.
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Table 1. Characteristics of 1,164 HIV-infected women in the Women’s Interagency HIV
Study December 6, 1995 through December 6, 2005
History of
Injection Drug
Use (IDU)
𝑛 = 439

No History of
Injection Drug
Use (IDU)
𝑛 = 725

𝑛 = 1,164

Age years

40 (35, 44)

33 (29, 39)

36 (31, 41)

African American race

273 (62%)

399 (55%)

672 (58%)

352 (208, 522)

348 (216, 505)

349 (213, 517)

208 (47%)

459 (63%)

667 (57%)

Characteristics a

Nadir CD4+ count cells/uL
Initiated antiretrovirals (ARTs)

a

Median (interquartile range) or number (percent)
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Table 2. Association of history of injection drug use with time to AIDS or death for 1,164
HIV-infected women in the Women’s Interagency HIV Study December 6, 1995 through
December 6, 2005
History of

No History of

Overall

Injection Drug

Injection Drug

Use (IDU)

Use (IDU)

𝑛 = 439

𝑛 = 725

𝑛 = 1,164

272 (62%)

307 (42%)

579 (50%)

2,368

4,721

7,090

Hazard ratio (95% CI)

1.72 (1.46, 2.03)

1

-

10-year risk (95% CI)

0.64 (0.59, 0.68)

0.46 (0.42, 0.49)

0.53 (0.50, 0.56)

10-year risk difference (95% CI)

0.19 (0.13, 0.24)

0

-

272 (62%)

307 (42%)

579 (50%)

9,804

20,692

30,496

Hazard ratio (95% CI)

1.53 (1.27, 1.85)

1

-

10-year risk (95% CI)

0.60 (0.54, 0.64)

0.46 (0.42, 0.50)

0.51 (0.48, 0.54)

10-year risk difference (95% CI)

0.14 (0.06, 0.22)

0

-

Unadjusted
AIDS cases and deaths
Person-years

Standardized a
AIDS cases and deaths
Person-years

a

IP weighted to account for confounding and selection bias due to age (spline), race, nadir

CD4 (spline), and ART initiation (time-varying)
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Figure 1. Kaplan-Meier estimated AIDS-free survival curves without accounting for any
covariates for 1,164 HIV-infected women with and without a history of injection drug use
(IDU) in the Women’s Interagency HIV Study December 6, 1995 through December 6, 2005
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Figure 2. Standardized estimated AIDS-free survival curves (accounting for age, race, nadir
CD4, and ART initiation) for 1,164 HIV-infected women with and without a history of
injection drug use (IDU) in the Women’s Interagency HIV Study December 6, 1995 through
December 6, 2005
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Supplemental Table 1. Example individual-level estimated exposure weights, drop out
weights, and combined weights for 1,164 HIV-infected women in the Women’s Interagency
HIV Study December 6, 1995 through December 6, 2005

ID

History of
Injection
Exposure
Time in Time out
Event Drop out
Drug Use
weight
(IDU)

Drop out Combined
weight
weight

34

0.00

0.080

Yes

No

No

0.515

1.000

0.515

34

0.08

0.170

Yes

No

No

0.515

1.000

0.515

34

0.17

0.208

Yes

No

Yes

0.515

1.001

0.516

36

0.00

0.080

No

No

No

1.191

1.000

1.191

36

0.08

0.170

No

No

No

1.191

1.000

1.191

36

0.17

0.225

No

No

Yes

1.191

1.001

1.192

37

0.00

0.080

Yes

No

No

1.007

1.000

1.007

37

0.08

0.170

Yes

No

No

1.007

1.000

1.007

37

0.17

0.227

Yes

Yes

No

1.007

1.000

1.007

38

0.00

0.080

No

No

No

0.949

1.000

0.949

38

0.08

0.170

No

No

No

0.949

1.000

0.949

38

0.17

0.250

No

No

No

0.949

0.999

0.948

38

0.25

0.330

No

No

No

0.949

0.999

0.948

38

0.33

0.420

No

No

No

0.949

0.998

0.947

38

0.42

0.427

No

Yes

No

0.949

0.997

0.946

66

0.00

0.080

Yes

No

No

0.545

1.000

0.545

66

0.08

0.170

Yes

No

No

0.545

1.000

0.545

66

0.17

0.250

Yes

No

No

0.545

0.999

0.545

66

0.25

0.330

Yes

No

No

0.545

0.999

0.544

66

0.33

0.378

Yes

No

Yes

0.545

0.998

0.544
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Supplemental Figure 1. Estimated log cumulative hazard curves without accounting for
any covariates calculated for 1,164 HIV-infected women with and without a history of
injection drug use (IDU) in the Women’s Interagency HIV Study December 6, 1995 through
December 6, 2005
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Supplemental Figure 2. Standardized estimates of the log cumulative hazard curves
(accounting for age, race, nadir CD4, and ART initiation) calculated for 1,164 HIV-infected
women with and without a history of injection drug use (IDU) in the Women’s Interagency
HIV Study December 6, 1995 through December 6, 2005
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